Literature DB >> 24516314

Epidemiological and clinical profile of patients with chronic myeloid leukemia at Health-Care Global, Bangalore Institute of Oncology.

K G Srinivas1, Shekar Patil1.   

Abstract

Health-Care Global, Bangalore Institute of Oncology is a cancer care center, which provides comprehensive care for cancer patients. Here, we present data of 350 patients diagnosed as cases of chronic myeloid leukemia over a period of 10 years. In our patient population, there was male predominance and majority of patients lied between the age group of 40 and 50 years. 90% patients were initially started on 400 mg dose of imatinib. About 30% of patient population required dose excalation due to inadequate response while 10% required dose descalation due to myelosuppression. 60% of patients had complete response by 3 months and 52% of patients had major molecular response by 1 year.

Entities:  

Keywords:  Bangalore; chronic myeloid leukemia; chronic phase

Year:  2013        PMID: 24516314      PMCID: PMC3902629          DOI: 10.4103/0971-5851.123746

Source DB:  PubMed          Journal:  Indian J Med Paediatr Oncol        ISSN: 0971-5851


  5 in total

1.  The story of chronic myeloid leukaemia.

Authors:  C G Geary
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

Review 2.  Milestones and monitoring in patients with CML treated with imatinib.

Authors:  Michael W Deininger
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

3.  The effects of imatinib on pregnancy outcome.

Authors:  Seonaid M Pye; Jorge Cortes; Patricia Ault; Alan Hatfield; Hagop Kantarjian; Richard Pilot; Gianantonio Rosti; Jane F Apperley
Journal:  Blood       Date:  2008-03-05       Impact factor: 22.113

Review 4.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

Review 5.  Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

Authors:  Elias Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

  5 in total
  2 in total

Review 1.  Summary of the published Indian data on chronic myeloid leukemia.

Authors:  Manish K Singhal; Manju Sengar; Reena Nair
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

Review 2.  Chronic Myeloid Leukemia in India.

Authors:  Prasanth Ganesan; Lalit Kumar
Journal:  J Glob Oncol       Date:  2016-07-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.